In contrast, treatment with the lipid soluble statin, lovastatin, an inhibitor of HMG-CoA reductase, the rate limiting enzyme in the cholesterol biosynthetic pathway, results in reduced cell proliferation and migration in breast cancer cells (Figure 7), likely via reducing cholesterol intracellular levels [39], and its effects are reversed by exogenous cholesterol addition. This evidence concerns the gene HMGCR and breast cancer.